---
url: https://www.servicesaustralia.gov.au/neurofibromatosis-type-1
title: Neurofibromatosis type 1 - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:21.544Z
source: servicesaustralia.gov.au
---
# Neurofibromatosis type 1

The PBS subsidises selumetinib for patients with neurofibromatosis type 1.

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with selumetinib under the _National Health Act 1953_, section 85 for patients with neurofibromatosis type 1.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing selumetinib.

## Treatment specifics

To be eligible for PBS-subsidised treatment with selumetinib, patients must be treated by either a:

-   specialist physician with expertise in neurofibromatosis
-   medical practitioner in consultation with a specialist physician with expertise in neurofibromatosis, if attendance isn’t possible due to geographic isolation.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised selumetinib to treat neurofibromatosis type 1 can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [neurofibromatosis type 1 - selumetinib - initial authority application form](/pb370?context=20)
-   relevant attachments.

### Applying for initial grandfather treatment

Applications for initial grandfather authority approval to prescribe PBS-subsidised selumetinib to treat neurofibromatosis type 1 can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [neurofibromatosis type 1 - selumetinib - initial grandfather authority application form](/pb371?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised selumetinib to treat neurofibromatosis type 1 can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
